HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
WEDNESDAY, July 13, 2022 (HealthDay News) -- The impact of the COVID-19 pandemic on antimicrobial resistance is addressed in a special report from the U.S. Centers for Disease Control and Prevention.
Noting that antimicrobial resistance was one of the main public health concerns prior to the COVID-19 pandemic, researchers examined the impact of COVID-19 on antimicrobial resistance.
The authors note that deaths from antimicrobial resistance decreased by 18 percent overall and nearly 30 percent in hospitals between 2012 and 2017 due to significant investments in prevention efforts. However, resistant hospital-onset infections and deaths increased at least 15 percent during the first year of the pandemic. U.S. hospitals saw increases in four of six types of health care-associated infections in a 2021 analysis, including infections resistant to antibiotics or antifungals. From 2019 to 2020, increases in resistant infections included a 78 percent increase in carbapenem-resistant Acinetobacter, a 60 percent increase in antifungal-resistant Candida auris, a 35 percent increase in carbapenem-resistant Enterobacterales, and a 13 percent increase in methicillin-resistant Staphylococcus aureus. To better respond to the challenges of antimicrobial resistance and emerging threats, the CDC recommends continuing to extend high-quality infection prevention and control training to all health care professionals; increasing infection prevention and control implementation in facilities beyond hospitals; and communicating clearly to the public regarding the spread of disease.
"We need to emphasize and expand the implementation of the effective prevention strategies that are already in CDC's toolbox to all health care facilities," Denise Cardo, M.D., director of the CDC Division of Healthcare Quality Promotion, said in a statement.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Published on July 13, 2022